Composition for promoting efficiency of somatic cell replication

Patent metadata

Field	Value
Publication number	US-12460177-B2
Application number	US-201916969045-A
Country	US
Kind code	B2
Filing date	Feb 12, 2019
Priority date	Feb 13, 2018
Publication date	Nov 4, 2025
Grant date	Nov 4, 2025

Abstract

The present invention relates to a composition for promoting the efficiency of somatic cell replication, comprising endothelin as an active ingredient. When somatic cells are treated with the composition of the present invention, H3K9me3, which is suspected to be a factor for the lowering success rate of nuclear substitution, is inhibited, and H3K4me3, which has the opposite effect, is increased to increase the success rate of nuclear substitution. Accordingly, the composition of the present invention increases the efficiency of somatic cell replication, thereby increasing the efficiency of producing pluripotent stem cells derived from nuclear substitution, and ultimately, the composition is expected to contribute to the development of cell therapeutic agents.

First claim

What is claimed is:

1 . A method of promoting somatic cell nuclear transfer efficiency, comprising:
a) contacting a donor cell with a composition comprising endothelin as an active ingredient, wherein the donor cell is a mesenchymal stem cell; and b) extracting the nucleus of the donor cell, wherein the endothelin induces a transition of H3K9me3 to H3K4me3 in the Apobec1 promoter region of the extracted nucleus, thereby enhancing the efficiency of somatic cell nuclear transfer when the nucleus extracted in step b) thereby promoting blastocyst formation efficiency is transferred to an oocyte.

2 . The method of claim 1 , wherein the endothelin is one or more selected from the group consisting of endothelin-1, endothelin-2, endothelin-3, endothelin modifier, big endothelin (big ET) and prepro endothelin (prepro ET).

3 . The method of claim 2 , wherein, among the 21 amino acids constituting endothelin, the endothelin modifier comprises the sequence of SEQ ID NO: 1 consisting of the amino acids 16 to 21 as is, and one or more of amino acids 1 to 15 are modified or deleted.

4 . The method of claim 2 , wherein the prepro ET and big ET comprise the amino acid sequence of SEQ ID NO: 1.

Assignees

• Seoul Nat Univ Hospital

Inventors

• Lee Eun Ju
• Kim Hyo-Soo

Classifications

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C07K14/57536 Primary

  Endothelin, vasoactive intestinal contractor [VIC] · CPC title

• C12N5/0604 Primary

  Whole embryos; Culture medium therefor · CPC title

• C12N15/877 Primary

  Techniques for producing new mammalian cloned embryos · CPC title